The estimated Net Worth of Venture Partners Ix, Llcarc... is at least $2.41 Milione dollars as of 2 July 2019. Venture Llcarc owns over 200,000 units of Beam Therapeutics stock worth over $2,412,000 and over the last 5 years Venture sold BEAM stock worth over $0.
Venture has made over 1 trades of the Beam Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Venture bought 200,000 units of BEAM stock worth $3,200,000 on 2 July 2019.
The largest trade Venture's ever made was buying 200,000 units of Beam Therapeutics stock on 2 July 2019 worth over $3,200,000. On average, Venture trades about 11,111 units every 0 days since 2019. As of 2 July 2019 Venture still owns at least 100,000 units of Beam Therapeutics stock.
You can see the complete history of Venture Llcarc stock trades at the bottom of the page.
Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr e Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeutics executives and other stock owners filed with the SEC include: